Myriam MAKHLOUFI

Myriam MAKHLOUFI has a diverse work experience spanning various companies and roles. Myriam is currently working as a Business Strategy Officer at TreeFrog Therapeutics since November 2021. Prior to that, they served as the Strategic Marketing & Planning Director at SEQENS CDMO from January 2019 to November 2021.

Before joining SEQENS CDMO, Myriam worked at Pierre Fabre Group from March 2015 to December 2018. Myriam held the position of Director of Corporate Development, Licensing & Acquisition, where they managed a team of 4 Business Development Managers and was responsible for the business development activities of Pierre Fabre Médicament, including oncology, prescription drugs, and consumer health.

From October 2011 to March 2015, Myriam worked as the Manager of Market Research & Strategic Planning at Astellas Pharma. Prior to that, they held the role of Business Analyst & Strategic Planning at Astellas Pharma France from October 2010 to September 2011.

Earlier in their career, Myriam worked at Bionest Partners, starting as an Analyst in M&A, Corporate Finance, Healthcare Sector from October 2007 to December 2009. Myriam then advanced to the position of Associate in M&A, Corporate Finance, Healthcare Sector from January 2010 to September 2010. Finally, they served as a Senior Consultant in Management Consulting from September 2004 to October 2007, where they were responsible for the commercial and strategic due diligence department for Private Equity clients.

Overall, Myriam MAKHLOUFI has demonstrated expertise in business strategy, marketing, planning, licensing, and acquisition, with a focus on the pharmaceutical and healthcare sectors.

Myriam Makhloufi completed their MSc degree in Biotechnology/Management from ESIEE (ex-ISTM) between 2001 and 2004. In 2012, they enrolled in the Future Leaders Programme at INSEAD but no end year is specified, suggesting that they may still be pursuing this program.